Meghan Elizabeth Sise, M.D.
This page shows the publications co-authored by Meghan Sise and David Leaf.
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. Eur J Cancer. 2021 Sep 02; 157:50-58.
Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. Am J Kidney Dis. 2021 Jun 24.
Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel. Am J Kidney Dis. 2021 06; 77(6):990-992.
Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney Int Rep. 2020 Oct; 5(10):1700-1705.
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. Am J Kidney Dis. 2020 07; 76(1):63-71.
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020 02; 31(2):435-446.
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019 12 06; 14(12):1692-1700.
Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 Oct; 9(10).
A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021 07; 100(1):196-205.
AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. J Am Soc Nephrol. 2021 01; 32(1):161-176.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.